Access to medicines – January 2020

The September 2019 Board meeting covered

• Updates on access topics (EURIPID/Orphan and Paediatrics Regulation)
• Draft Regulation on HTA
• COM’s Biosimilar Stakeholder event

Access to medicines – Compounding

Position paper

• To be discussed under agenda point 7.6.1

EDQM consultation | FEEDBACK NEEDED

• EDQM has sent question on compounding practices for parenteral preparations (see HERE)
• Compounding leads are working on a response (deadline end February)
• Any additional comments?

GSASA request | FEEDBACK NEEDED

• GSASA has reached out to EAHP in relation to an EDQM monograph on eye drops
• GSASA disagrees with EDQMs suggestions and has asked EAHP to engage in dialogue with EDQM in case the issue brought forward by GSASA is relevant to HPs other than those in Switzerland
• The request email (see HERE) is only available in German
• GSASA’s response (see HERE) is available in English

HTA

Draft Regulation on HTA

• Still stuck in Council
• Unclear if Croatian Presidency will advance the file

EUnetHTA

• Next forum will be held on 2nd April 2020 in Amsterdam (more information HERE)
• Last year Frank Jørgensen attended since event coincided with EAHP’s Board meeting
• Board leads are discussing about attendance

Procurement

Procurement event with authorities on 28th April

• Invitations have been sent | feedback is still missing from Greece, Sweden and the UK (see list of participants from 23/1 HERE)
• See draft agenda HERE
• Response deadline 7 February

Medicines for Europe’s Procurement WG | FEEDBACK NEEDED

• Working group had a call with the leads in October
• Other calls should be set up in February and June
• A face-to-face meeting in Gothenburg has been requested. Update: this is no longer feasible for Medicines for Europe; alternative solutions (e.g. face-to-face meeting in Brussels) have been requested
• DM also would like to discuss a plan for action with the Board

Patient safety

ESA Patient Safety Summit | DECISION NEEDED

• PH and AB will participate
• As partner of the summit EAHP needs to decide on the endorsement of the consensus statement (see HERE) – Note: document was already shared with the Board for endorsement by 27/1

Promotion of role on patient safety | FEEDBACK NEEDED

• DM suggested to start promoting the role of HPs more effectively after the patient safety summit
• She linked her suggested to NM’s comments on clinical risk management

FIP Statement on patient safety

• FIP will be developing a position on patient safety in 2020